Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Part of paid clinical trials in New York, New York.

Sponsor
Click Therapeutics, Inc.
Study ID
NCT05853900
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ReMMi-D Digital Therapeutic — DEVICE
    Evaluate the effectiveness and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.

Study Details

Randomized study of two digital therapeutics for the prevention of episodic migraine

Key Dates

Start date
Mar 28, 2023
Status verified
Jul 2025
Primary completion
May 7, 2024
Completion
May 7, 2024

Study Design

Enrollment
568 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Mobile application A as a software-based intervention for the preventive treatment of episodic migraine in late adolescents and adults.
  • Experimental: Arm B
    Mobile application B is an investigational digital therapeutic that is being studied for the preventative treatment of episodic migraine.

Primary Outcome Measure

Change in MMD (Monthly Migraine Days) [ Time Frame: Baseline (28-day Run-in Period) to Week 12 (previous 28 days, Week 9 through Week 12) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Click TherapeuticsNew YorkNew York10013-

Find similar trials in New York, NY

By condition
Migraine
By specialty
Neurology
By research site
Click Therapeutics· New York, NY

Related Studies